| Literature DB >> 29546209 |
Abstract
The modern success story of vaccinations involves a historical chain of events that transformed the discovery that vaccines worked, to administering them to the population. We estimate the number of lives saved and morbidity reduction associated with the discovery of the first human cell strain used for the production of licensed human virus vaccines, known as WI-38. The diseases studied include poliomyelitis, measles, mumps, rubella, varicella (chicken pox), herpes zoster, adenovirus, rabies and Hepatitis A. The number of preventable cases and deaths in the U.S. and across the globe was assessed by holding prevalence rates and disease-specific death rates constant from 1960-2015. Results indicate that the total number of cases of poliomyelitis, measles, mumps, rubella, varicella, adenovirus, rabies and hepatitis A averted or treated with WI-38 related vaccines was 198 million in the U.S. and 4.5 billion globally (720 million in Africa; 387 million in Latin America and the Caribbean; 2.7 billion in Asia; and 455 million in Europe). The total number of deaths averted from these same diseases was approximately 450,000 in the U.S., and 10.3 million globally (1.6 million in Africa; 886 thousand in Latin America and the Caribbean; 6.2 million in Asia; and 1.0 million in Europe).Entities:
Keywords: demography; mortality; public health; vaccines
Year: 2017 PMID: 29546209 PMCID: PMC5689800 DOI: 10.3934/publichealth.2017.2.127
Source DB: PubMed Journal: AIMS Public Health ISSN: 2327-8994
Viral diseases treated with vaccines prepared using the WI-38 cell strain or its derivatives, year each vaccine was introduced, annual cases, pre-vaccine annual deaths, and cases and deaths averted or treated from each disease from year of introduction to 2015 (with 95% coverage).
| Disease | YearIntroduced | Vaccineannual cases(U.S., 1960) | Pre-vaccineannual deaths(U.S.) | Cases averted or treated with 95% coverage | Deaths averted with 95% coverage |
| Poliomyelitis | 1963 | 36,110 | 5,865 | 2,547,045 | 413,692 |
| Measles | 1969–70 | 530,217 | 440 | 34,137,129 | 28,329 |
| Mumps | 1967 | 162,344 | 39 | 10,792,317 | 2,593 |
| Rubella | 1969 | 47,745 | 17 | 3,073,981 | 1,095 |
| Varicella (chicken pox) | 1995–96 | 4,085,120 | 107 | 133,691,807 | 3,436 |
| Hepatitis A | 1996 | 117,333 | 137 | 3,674,988 | 4,291 |
| Rabies | 1974 | 18,000 | - | 10,000,000 | - |
| Adenovirus | 1964 | 11,138 | - | 375,619 | - |
| Total (U.S.) | 5,017,007 | 6,603 | 198,292,887 | 453,435 |
Estimates of cases and deaths were obtained from the following sources:
http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/G/cases-deaths.pdf
Roush SW, Murphy TV (2007) JAMA 298: 2155-2163.
http://jama.jamanetwork.com/article.aspx?articleid=209448.
Population estimates were obtained from the following sources:
http://www.census.gov/population/international/data/worldpop/table_population.php.
http://www.census.gov/prod/cen1990/cph2/cph-2-1-1.pdf.
# The majority of cases of rabies treated with the WI-38 based vaccine occurred after the disease appeared rather than as a preventative measure (http://www.rightdiagnosis.com/r/rabies/stats.htm). The value of the WI-38 based rabies vaccine was that it eliminated the painful side effects associated with the previous vaccine made in neuronal tissue.
* The adenovirus was developed in 1966 and first administered to military personnel in 1971. Estimates provided here assume .04% of the total U.S. population served in the armed forces annually; prevalence of adenovirus among military forces is 1.1% annually; and these calculations apply only for the years 1971–1999 and 2011–2016 when the WI-38 related adenovirus vaccine was administered.